Skip to main content
Medicamen Biotech Ltd. logo

Medicamen Biotech Ltd. — Investor Relations & Filings

Ticker · MEDICAMEQ ISIN · INE646B01010 LEI · 894500T0ULD27B7W4Y03 BSE.NS Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2024-01-12 Regulatory Filings
Country IN India
Listing BSE.NS MEDICAMEQ

About Medicamen Biotech Ltd.

https://www.medicamen.com/

Medicamen Biotech Ltd. specializes in the research, development, and manufacturing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities compliant with international quality standards, including WHO-GMP. Its product portfolio encompasses various therapeutic segments such as oncology, cardiology, central nervous system, and anti-infectives, delivered through dosage forms like tablets, capsules, and liquid orals. A significant strategic focus is placed on its specialized oncology division, which develops complex generic formulations. The company serves global markets, leveraging its research and development capabilities to provide high-quality healthcare solutions. Its operations are supported by dedicated R&D centers focused on formulation development and process chemistry.

Recent filings

Filing Released Lang Actions
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming details of securities dematerialized/rematerialized for the quarter ended December 31, 2023. It is a compliance certification addressed to stock exchanges, signed by the company secretary. The document is short (1544 characters) and does not contain financial statements or detailed financial data. It is primarily a regulatory compliance certificate rather than a financial report or announcement of voting results, management changes, or capital changes. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and certification documents.
2024-01-12 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice dated December 30, 2023, addressed to stock exchanges regarding the closure of the trading window for directors and designated persons. It mentions the upcoming declaration of unaudited financial results for the quarter and nine months ending December 31, 2023, but does not contain any financial data or results itself. The document is an announcement related to trading restrictions ahead of financial results disclosure, not the financial report or earnings release itself. Given its brevity (1640 characters) and nature as an announcement, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2024-01-02 English
Updates
Interim / Quarterly Report Classification · 95% confidence The document is a formal communication from Medicamen Biotech Limited to stock exchanges (BSE and NSE) dated November 10, 2023. It announces the approval of Un-Audited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2023. It references Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to quarterly financial results disclosures. The document includes the financial results as Annexure-A and a Limited Review Report as Annexure-B. The document is relatively short (2279 characters) and serves as an announcement of the financial results and the board meeting outcome rather than the full detailed financial report itself. This fits the profile of an Interim / Quarterly Report (IR) because it contains substantive financial data for a period shorter than a full fiscal year and is not merely a notice or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2024
2023-12-01 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 95% confidence The document is a short communication (1380 characters) addressed to stock exchanges regarding the publication of un-audited financial results for the quarter and half year ended September 30, 2023. It references the approval of these results by the Board of Directors and mentions the publication of an extract in newspapers. The document does not contain the actual financial statements or detailed analysis but serves as a notification of the publication of these results. According to the 'MENU VS MEAL' rule, such a brief announcement about the publication of financial results without the full report itself should be classified as a Report Publication Announcement (RPA).
2023-11-11 English
Related Party Transactions
Regulatory Filings Classification · 95% confidence The document is a disclosure of related party transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It provides detailed information on related party transactions for the half year ended September 30, 2023. The document includes transaction values, approval status by the audit committee, and details of parties involved. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an announcement of voting results, management changes, or legal proceedings. It is a regulatory disclosure specific to related party transactions, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories and is a compliance disclosure under SEBI regulations.
2023-11-10 English
Outcome of Board Meeting
Regulatory Filings
2023-11-10 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.